The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis

European Journal of Pharmacology

Volumn 432, Issue 2-3, 2001, Pages 187-194

  McClanahan, Thomas B ^a,c   Hicks, Gary W ^a   Morrison, Angela L ^a   Peng, Yun Wen ^a   Janiczek Dolphin, Nancy ^a   Mertz, Thomas E ^a   Sullivan, Mark E ^b   Morser, John ^b   Juneau, Paul L ^a   Leadley, Robert ^a  

^a PFIZER INC   (United States)

^b BAYER AG   (Germany)

^c NONE   (United States)

Author keywords

Electrolytic injury; Enoxaparin sodium; Factor Xa inhibitor; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; N [2 (5 AMIDINO 2 HYDROXYPHENOXY) 3,5 DIFLUORO 6 [3 (1 METHYL 1H 2 IMIDAZOLIN 2 YL)PHENOXY] 4 PYRIDINYL] N METHYLGLYCINE; N [2 [5 AMIDINO 2 HYDROXYPHENOXY] 6 [3 (1 METHYL 1H IMIDAZOLIN 2 YL) PHENOXY] 3,5 DIFLUOROPYRID; PROTHROMBIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD CLOTTING; CONTROLLED STUDY; DOG; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; FEMORAL ARTERY; FEMORAL VEIN; MALE; NONHUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOGENESIS; THROMBUS; VEIN THROMBOSIS;

AMIDINES; ANIMALS; ANTICOAGULANTS; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROLYSIS; ENOXAPARIN; FACTOR XA; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; PYRIDINES; THROMBIN TIME; THROMBOSIS; TIME FACTORS; VENOUS THROMBOSIS;

EID: 0035824736     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)01090-1     Document Type: Article

References (26)

1. Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits
2. Factor Xa inhibitors
3. Unfractionated and low-molecular-weight heparins in acute coronary syndromes: Current recommendations
4. Novel anticoagulants based on direct inhibition of thrombin and factor Xa
5. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor
6. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis
7. Comparison of enoxaparin, hirulog, and heparin as adjunctive therapy during thrombolysis with rtPA in the stenosed canine coronary artery
8. Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin
9. Pharmacodynamic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation factor Xa
10. Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model
11. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition
12. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis
13. Discovery of N-[2-[5-[Amino (imino)-methyl]-2-hydroxyphenoxy]-3,5-difluoro-6-[3-(4,5-dihydro-1-methyl- 1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylglycine (ZK-807834): A potent selective, and orally active inhibitor of the blood coagulation factor Xa
14. Antithrombotic effect of YM-75466 is seperated from its effect on bleeding tiome and coagulation time
15. Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats
16. The pharmacokinetics of BX-807834, a potent, selective factor Xa inhibitor in animals
17. The efficacy and safety of BX-807834, a potent, selective factor Xa inhibitor, in animal models
18. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa
19. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A
20. Novel antithrombotic drugs in development
21. Comparison of the in vivo anticoagulant properties of standard heparin and the highly elective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis
22. Low-molecular weight heparins
23. New antithrombotic agents
24. Nonpeptide factor Xa inhibitors: 1. Studies with SF303 and SK549, a new class of potent antithrombotics
25. Low-molecular weight heparin should replace unfractionated heparin in the management of acute coronary syndromes